Posts Tagged ‘biotech’

Financial Growing Pains of a Biotech | The Scientist Magazine(R)

August 27, 2017

Cell-free biotech will make for better products

May 8, 2017

Cell-free biotech will make for better products Gr8 screening, quickly making proteins from oligos HT @EmilyLeproust

“A typical recipe for making cell-free protoplasmic gloop is this. Take four litres of culture containing E. coli (a gut bacterium favoured by genetic engineers). Split the bacterial cells open by forcing them through a tiny valve at pressure, thus shredding their membranes and DNA, and liberating the ribosomes. Incubate the resulting mixture at 37°C for an hour, to activate enzymes called exonucleases that will eat up the fragmented DNA. Centrifuge, to separate the scraps of cell membrane and other detritus from the gloop that contains ribosomes. Dialyse to remove unwanted ions. Then stir in amino acids (the building blocks of proteins), sugar and an
energy-carrying molecule called adenosine triphosphate (ATP) to power the process. Finally, add a pinch of new DNA to taste, to tell the gloop which proteins it is supposed to produce.”

The Man Who Kicked Off the Biotech Revolution – Issue 44: Luck – Nautilus

January 30, 2017

The Man Who Kicked Off…#Biotech by @CarlZimmer H Smith for discovering restriction enzymes + a history of the term

“Trying to make sense of the failure, Wilcox suggested to Smith that the bacteria were destroying the viral DNA. He based his suggestion on a hypothesis proposed a few years earlier by Werner Arber, a microbiologist at the University of Geneva. Arber speculated that enzymes could restrict the growth of viruses by chopping up their DNA, and dubbed these hypothetical molecules “restriction enzymes.”” “}}

The Billion Dollar Pharma Startup that Silicon Valley Has Totally Missed

January 21, 2017

The…Pharma Startup…Silicon Valley Has Totally Missed Run by QVT alum; focuses on better incentivizing scientists

UPDATED: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus

July 14, 2015

$BMY rips up its R&D group…800-plus [affected] Trend of pruning spoke cities & growing #hub ones HT @JorgensenWL

“Bristol-Myers Squibb’s big reorganization fits into the industry’s new model for R&D. Large, scattered groups are out as big
organizations gravitate toward the big hubs. GlaxoSmithKline ($GSK) and Amgen ($AMGN) have offered two recent examples of that trend, which has benefited hubs like Boston/Cambridge and the Bay Area while inflicting painful cuts in outlying areas. Biopharma companies are also concentrating on core areas, sometime shedding early-stage work–reflected in Merck’s ($MRK) recent downsizing at the newly acquired Cubist and the big asset swap that occurred between GlaxoSmithKline and Novartis ($NVS).”